Texas-based chicken restaurant to open 4 locations in the region
Texas-based Layne's Chicken is eyeing four locations in the Miami Valley.
[DOWNLOAD: Free WHIO-TV News app for alerts as news breaks]
Business partners Mauricio Blanco and Marvin Monroy told 1851 Franchise that they are developing four Layne's in the Dayton region.
Blanco said they are looking to make a 'big impact' in the area.
TRENDING STORIES:
Student dies after accidentally falling from balcony during senior class trip
Police looking for man, woman accused of paying $1K less for items after altering barcodes
Local village council member dies at 54
Columbus Retail Team also posted on social media that Layne's is looking for sites to purchase in the area.
Layne's Chicken Fingers was started in Texas in 1994 and is known for its 'soon-to-be-famous' chicken fingers and house-made sauces.
We are working to learn where the locations will be and when they are expected to open.
We will continue to follow this story.
[SIGN UP: WHIO-TV Daily Headlines Newsletter]
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
19 minutes ago
- Yahoo
Small Firm, Big Achievement: The Poirier Group Earns Spot on Forbes List of Best Management Consulting Firms
Toronto, Ontario--(Newsfile Corp. - June 9, 2025) - The Poirier Group (TPG), a Toronto-based boutique consulting firm has earned a coveted spot on the Forbes 2025 list of America's Best Management Consulting Firms, distinguishing itself as a top performer in a highly competitive industry landscape. Forbes, in partnership with global data provider Statista, conducted comprehensive surveys of both clients and industry experts. Out of thousands of management consulting firms across North America—an industry that includes over 730,000 consultants—only 191 firms made the cut this year. The Poirier Group based in Toronto, is also one of just a handful of Canadian consultancies to receive this honor in 2025, demonstrating its ability to compete and excel at an international level. Forbes 2025 America's Best Management Consulting Firms To view an enhanced version of this graphic, please visit: This recognition arrives at a pivotal time when companies across most industry sectors are navigating unprecedented levels of change: rapid advancements in technology, evolving workplace dynamics post-pandemic, widespread burnout, and public policy shifts affecting everything from environmental standards to diversity and equity. The current climate has created a surge in demand for agile, innovative consulting partners—especially those capable of integrating next-generation solutions like generative artificial intelligence (GenAI) to advance business competitiveness. TPG's inclusion on the Forbes list—and particularly, its recognition in the Artificial Intelligence consulting category—is a testament to the firm's ability to not only meet but anticipate and exceed evolving client needs. TPG has already positioned itself by going beyond basic automation to applying AI to accelerate performance, solve complex challenges, and drive meaningful transformation. David Poirier, CEO - The Poirier Group To view an enhanced version of this graphic, please visit: "We are absolutely thrilled to be recognized on the Forbes 2025 list," said David Poirier, CEO at The Poirier Group. "As a boutique firm, we pride ourselves on personalized service, deep operational expertise, an unwavering focus on client impact and delivering a better consulting experience. To be acknowledged alongside global consulting giants is both humbling and energizing for our entire team." Punching Above Their Weight The Poirier Group has built its brand and reputation through results. The firm specializes in operational excellence, helping clients across key sectors such as retail, supply chain, manufacturing, private equity, healthcare, and government to improve performance and achieve long-term sustainability. Rather than offering broad, theoretical strategies out of the box, TPG focuses on hands-on, execution-driven consulting—delivering consistently and producing measurable outcomes, from cost reduction and productivity gains to strategic transformation and technology adoption. And, because most change initiatives come with the price of inherent resistance, TPG has indoctrinated a proven collaborative approach that achieves strategic alignment and builds workforce momentum to adapt to a new way of working, enhancing agility and the adoption of change. Their disciplined and personalized approach has earned the firm repeat business and client referrals, which played a critical role in its Forbes recognition. According to Statista, the rankings are based on two surveys: An expert survey of over 10,000 partners and senior executives at consulting firms, who were asked to recommend firms across 16 industries and 17 functional areas. A client survey involving more than 1,200 company executives evaluated their consulting partners based on real project experiences from the past four years. Self-nominations were not accepted, making TPG's appearance on the list a clear validation of its reputation in the industry and amongst its clients. A Canadian Voice in a Crowded U.S. Market While the list primarily highlights top consulting firms operating in the United States, The Poirier Group's inclusion demonstrates the cross-border strength and credibility of Canadian firms in the North American marketplace. Being one of only a few Canadian consulting firms to appear on this year's list amplifies the significance of their achievement and reflects the firm's growing influence beyond its home country. "We've always believed that size or geography shouldn't limit our impact," said Jared Frederici, Partner. "We take pride in our ability to provide a high-touch service and rapid delivery, with a flexible approach that blends onsite and virtual work. This resonates with clients who require the least disruption to continued operations. We demonstrate empathy fashioned by our experience with most of our consulting team having come from industry. This perspective ensures that we deliver pragmatic solutions that are achievable and sustainable. We work with clients who want a real partnership—one they can count on to advance their goals and build a winning culture." Consulting in a Time of Disruption The consulting industry itself is evolving rapidly with the rise of GenAI shifting client expectations dramatically. Research from the IBM Institute for Business Value indicates that 86% of consulting clients are actively looking for firms that offer AI-enhanced services—not just basic tools, but advanced applications that can help reshape entire business models. As a Forbes-recognized firm in the Artificial Intelligence category, The Poirier Group is already ahead of that curve. Its consultants are helping clients unlock value from GenAI not by treating it as a one-size-fits-all solution, but by applying it strategically to areas like workflow automation, predictive analytics, digital twin modeling, and performance optimization. The Poirier Group - Team Photo at Corporate Retreat To view an enhanced version of this graphic, please visit: What's Next for The Poirier Group This recognition by Forbes represents not just a milestone, but a springboard for The Poirier Group. The firm is expanding its capabilities in emerging technologies, strengthening its presence in high-growth sectors, and continuing to invest in its people—ensuring they remain ahead of the curve in a fast-changing business environment. "Being listed among America's best consulting firms is a great honor, but our focus remains the same: helping our clients thrive," said Anita Patel, Director. "That's the standard we hold ourselves to every day." The full list of America's Best Management Consulting Firms 2025 can be viewed at The Poirier Group To view an enhanced version of this graphic, please visit: About The Poirier Group The Poirier Group is a boutique management consulting firm based in Toronto, Canada. Now in its 20th year with 500 plus projects completed, it focuses on operational excellence and business transformation, leading the way in results-driven consulting services across North America and the Caribbean. For more information, visit: Media Contact:Tina ForthMarketing & CommunicationsThe Poirier Group905 To view the source version of this press release, please visit Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
25 minutes ago
- Yahoo
Celebrating 50 Years of Its Commitment to Family and Flavor, John Soules Foods Becomes Soules Foods
The company sets the table for its next chapter with a fresh brand identity and commitment to Great Food, Made Simple. TYLER, Texas, June 9, 2025 /PRNewswire/ -- John Soules Foods, a family-owned, Texas-based leading national food company is reintroducing itself to the world as Soules Foods – a new name that reflects its deep heritage and bold future. Founded in 1975 in Tyler, Texas, the company has grown from a humble hamburger patty producer into a national leader in fully cooked and ready-to-cook chicken and beef products found in homes, restaurants, and grocery stores across the country. The shift to Soules Foods honors that 50-year legacy while making room for the next generation of growth, innovation, and flavor. As the fourth generation of the Soules family joined the company this year, Soules Foods will continue its commitment to deliver more than just food, providing solutions that empower in both home and restaurant kitchens across the country. "We believe our new name and logo pay the proper respect to our 50 years in business, while communicating a fresh outlook for our future," said John Soules Jr., Co-CEO. "We now have the fourth generation of our family working in the business, and we are excited to build the future for this generation and the ones that follow." In tandem with the corporate rebrand, the company's retail brand will transition from John Soules Foods to Soules Kitchen, complete with a new logo, refreshed packaging, and updated look now rolling out in refrigerated and frozen aisles nationwide. Backed by decades of expertise, a commitment to quality, and its legacy as America's #1 fajita strips brand, Soules Kitchen will continue to offer the same high-protein, ready-to-eat favorites—like grilled chicken, steak strips and breaded chicken nuggets, strips, and bites—designed to help busy families get delicious meals on the table faster. "We're excited about this new chapter and remain committed to delivering on our purpose of Great Food, Made Simple—just with a fresh new look," said Mark Soules, Co-CEO. ABOUT SOULES FOODSSoules Foods is a leading national producer of ready-to-eat and ready to-cook chicken and beef products and is the #1 retail producer of chicken and beef fajitas in the U.S. Established in 1975 by John Soules Sr., the company is now in its fourth generation of family leadership and remains headquartered in Tyler, Texas, with additional facilities in Gainesville, Georgia, and Valley, Alabama. Soules Foods is proud to serve Great Food, Made Simple to retail, foodservice distributors and restaurants across the U.S. For more information about Soules Foods and its retail brand, Soules Kitchen, visit and check out our social media pages on Facebook, Instagram, TikTok, and Pinterest. Media ContactDani Rowdrow@ View original content to download multimedia: SOURCE Soules Foods Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
29 minutes ago
- Yahoo
Harrow Acquires U.S. Commercial Rights to BYQLOVI™ (Clobetasol Propionate Ophthalmic Suspension) 0.05% from Formosa Pharmaceuticals
TAIPEI, June 9, 2025 /PRNewswire/ -- Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, and Taiwan-based Formosa Pharmaceuticals ("Formosa", today announced a licensing agreement, whereby Harrow has acquired the exclusive U.S. commercial rights for BYQLOVI™ (clobetasol propionate ophthalmic suspension) 0.05%. BYQLOVI was recently approved by the U.S. Food and Drug Administration (FDA) for the treatment of post-operative inflammation and pain following ocular surgery and is the first new ophthalmic steroid in its class in over 15 years. Harrow expects BYQLOVI to be available in the fourth quarter of 2025. "We are thrilled to soon launch BYQLOVI, a truly clinically differentiated topical corticosteroid, into a U.S. market that now exceeds 7 million annual ophthalmic surgeries," said Mark L. Baum, Chief Executive Officer of Harrow. "With compelling efficacy, extraordinary safety, and patient‑friendly dosing, BYQLOVI has the potential to shift the paradigm in the multi-billion-dollar U.S. post-surgical care ophthalmic segment." "Harrow's commitment to innovation, patient access, and physician engagement closely aligns with our mission to promote unique clinical advancements that improve patient outcomes," said Erick Co, President and CEO of Formosa Pharmaceuticals. "We are confident that Harrow's leadership in the U.S. eyecare space will ensure BYQLOVI's successful adoption among surgeons and eyecare professionals – and ultimately, better post-surgical experiences for U.S. patients." BYQLOVI, a high-potency ophthalmic corticosteroid formulated using Formosa's proprietary APNT® nanoparticle formulation technology, delivers a highly uniform suspension that minimizes particle setting and provides consistent dosing. Its pharmacologic performance and clinical outcomes position it as a best‑in‑class option for post-operative inflammation and pain. Key highlights of BYQLOVI include: Best-in-Class Pain Relief with 77% and 85%, respectively, of patients in supportive pivotal clinical studies reporting no pain at Day 4 post-surgery; 82% and 87%, respectively, reporting no pain at Day 8 post-surgery. Best-in-Class Inflammation Clearance with 33% and 30%, respectively, of patients in supportive pivotal clinical studies with zero cell counts in the anterior chamber at Day 8 post-surgery. Safety Benefits with only 1.4% of patients experiencing elevated intraocular pressure (IOP), a substantially lower rate compared to other ophthalmic steroids. Best-in-Class Post-Surgical Dosing at 1 drop BID dosing for 14 days on label; without the need for a loading dose and a maintenance phase. About BYQLOVI™ (clobetasol propionate ophthalmic suspension) 0.05% BYQLOVI (clobetasol propionate ophthalmic suspension) 0.05%, for topical ophthalmic use INDICATIONS AND USAGE BYQLOVI is a corticosteroid indicated for the treatment of post-operative inflammation and pain following ocular surgery. CONTRAINDICATIONS BYQLOVI is contraindicated in most active viral diseases of the cornea and conjunctiva, including epithelial herpes simplex keratitis (dendritic keratitis), vaccinia, and varicella, and also in mycobacterial infection of the eye and fungal diseases of ocular structures. WARNINGS AND PRECAUTIONS Intraocular Pressure (IOP) Increase: Prolonged use of corticosteroids may result in glaucoma with damage to the optic nerve, defects in visual acuity and fields of vision. Steroids should be used with caution in the presence of glaucoma. If this product is used for 10 days or longer, IOP should be monitored. Cataracts: Prolonged use of corticosteroids may result in posterior subcapsular cataract formation. Delayed Healing: The use of steroids after cataract surgery may delay healing and increase the incidence of bleb formation. Corneal and Scleral Melting: In those diseases causing thinning of the cornea or sclera, perforations have been known to occur with the use of topical steroids. The initial prescription and renewal of the medication order should be made by a physician only after examination of the patient with the aid of magnification, such as slit lamp biomicroscopy, and where appropriate, fluorescein staining. Bacterial Infections: Prolonged use of corticosteroids may suppress the host response and thus increase the hazard of secondary ocular infections. In acute purulent conditions, steroids may mask infection or enhance existing infection. If signs and symptoms fail to improve after 2 days, the patient should be reevaluated. Viral Infections: Employment of a corticosteroid medication in the treatment of patients with a history of herpes simplex requires great caution. Use of ocular steroids may prolong the course and may exacerbate the severity of many viral infections of the eye (including herpes simplex). Fungal Infections: Fungal infections of the cornea are particularly prone to develop coincidentally with long-term local steroid application. Fungus invasion must be considered in any persistent corneal ulceration where a steroid has been used or is in use. Fungal culture should be taken when appropriate. ADVERSE REACTIONS Ocular adverse reactions occurring in ≥ 1% of subjects in clinical studies who received BYQLOVI included eye inflammation (2%), corneal edema (2%), anterior chamber inflammation (2%), cystoid macular edema (2%), intraocular pressure elevation (1%), photophobia (1%) and vitreous detachment (1%). Many of these reactions may have been the consequence of the surgical procedure. USE IN SPECIAL POPULATIONS Pregnancy. There are no adequate and well-controlled studies of BYQLOVI administration in pregnant women to inform a drug-associated risk. For additional information about BYQLOVI™, please see the Full Prescribing Information. About Formosa Pharmaceuticals Formosa Pharmaceuticals, Inc. ( is a clinical stage biotechnology company with primary focus in the areas of ophthalmology and oncology. The company's proprietary nanoparticle formulation technology (APNT®), through which BYQLOVI was developed, improves the dissolution and bioavailability of APIs for topical, oral, and inhaler administration. Resulting formulations have high uniformity, purity, and stability, thereby allowing the utilization of poorly soluble or extremely potent drug agents which otherwise may face insurmountable challenges in safety, delivery, and penetration to target tissues. For more details about Formosa Pharma and APNT®, visit About Harrow Harrow, Inc. (Nasdaq: HROW) is a leading eyecare pharmaceutical company engaged in the discovery, development, and commercialization of innovative ophthalmic pharmaceutical products for the North American market. Harrow helps eyecare professionals preserve the gift of sight by making its portfolio of pharmaceutical products accessible and affordable to millions of patients each year. For more information about Harrow, please visit Forward-Looking Statements This press release contains "forward-looking statements" within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this release that are not historical facts may be considered such "forward-looking statements." Forward-looking statements are based on management's current expectations and are subject to risks and uncertainties which may cause results to differ materially and adversely from the statements contained herein. Some of the potential risks and uncertainties that could cause actual results to differ from those predicted include, among others, risks related to: liquidity or results of operations; our ability to successfully implement our business plan, develop and commercialize our products, product candidates and proprietary formulations in a timely manner or at all, identify and acquire additional products, manage our pharmacy operations, service our debt, obtain financing necessary to operate our business, recruit and retain qualified personnel, manage any growth we may experience and successfully realize the benefits of our previous acquisitions and any other acquisitions and collaborative arrangements we may pursue; competition from pharmaceutical companies, outsourcing facilities and pharmacies; general economic and business conditions, including inflation and supply chain challenges; regulatory and legal risks, including litigation matters, and other uncertainties related to our pharmacy operations and the pharmacy and pharmaceutical business in general; physician interest in and market acceptance of our current and any future formulations and compounding pharmacies generally. These and additional risks and uncertainties are more fully described in Harrow's filings with the Securities and Exchange Commission (SEC), including its Annual Report on Form 10-K for the year ended December 31, 2023, subsequent Quarterly Reports on Form 10-Q, and other filings with the SEC. Such documents may be read free of charge on the SEC's web site at Undue reliance should not be placed on forward-looking statements, which speak only as of the date they are made. Except as required by law, Harrow undertakes no obligation to update any forward-looking statements to reflect new information, events, or circumstances after the date they are made, or to reflect the occurrence of unanticipated events. View original content to download multimedia: SOURCE Formosa Pharmaceuticals Inc. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
